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Abstract 
Introduction Staphylococcus aureus bacteremia (SAB) is a high-risk infection and feared 
complication related to hemodialysis. This study aimed to investigate incidence and risk factors for 
SAB depending on hemodialysis access type. 
Methods The Danish National Registry on Regular Dialysis and Transplantation was used to 
identify patients from January 1, 1996 to December 31, 2011 with end-stage kidney disease. 
Information on SAB was obtained from the national SAB Database. Patients were followed until 
death, the first episode of SAB, or end of study (December 31, 2011). Independent risk factors were 
assessed by multivariable Poisson regression with time-updated exposure variables.  
Findings 9997 patients were included. The initial modality of renal replacement therapy was 
hemodialysis in 6826 patients and peritoneal dialysis in 2882 patients; 289 patients had pre-emptive 
kidney transplantation. SAB occurred in 1278 patients (12.8%). The incidence rate of SAB declined 
after 90 days and leveled off after 270 days in hemodialysis, peritoneal dialysis and kidney 
transplanted. As compared to peritoneal dialysis, the adjusted rate ratio (RR) for SAB was 7.42 
(95% CI 5.63-9.79) in uncuffed central venous catheter (CVC), 5.68 (95% CI 4.39-7.36) in cuffed 
CVC, 4.43 (95% CI 2.10-9.53) in arteriovenous graft and 3.40 (95% CI 2.79-4.15) in arteriovenous 
fistula. SAB risk did not differ between uncuffed- and cuffed CVC. The risk of SAB was increased 
during the first three months of renal replacement therapy especially for CVC (RR 11.37 (95% CI 
7.09-18.22)) compared with peritoneal dialysis. Diabetes mellitus (RR 1.35 (95% CI 1.20-1.51)) 
and male sex (RR 1.15 (95% CI 1.03-1.29)) were also associated with SAB.           
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Discussion Patients on hemodialysis had a high incidence rate of SAB, particularly those 
undergoing hemodialysis via CVC. SAB risk was comparable for cuffed- and uncuffed CVC. 
Diabetes mellitus, male sex, and the first three months in renal replacement therapy in particular 
CVC were independently associated with SAB.    
Keywords  
Staphylococcus aureus bacteremia, hemodialysis access type, renal replacement therapy   
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Background 
Staphylococcus aureus bacteremia (SAB) is a serious, common complication of hemodialysis (1-
17). Several characteristics contribute to the increased risk of SAB among hemodialysis patients, 
including the need for repeated invasive procedures, disruption of the skin barrier, and 
compromised immune system related to uremia (10;18).  
Although different forms of hemodialysis intravascular access are known to confer different risks of 
SAB (15;19), the incidence rate and risk factors for SAB according to the type of hemodialysis 
vascular access is not well studied. 
The aim of this study was 1) to estimate the incidence of SAB according to form of vascular access 
(uncuffed-, cuffed central venous catheter (CVC), arteriovenous graft and arteriovenous fistula) and 
2) to identify risk factors for SAB among hemodialysis dependent patients. 
 
Materials and Methods  
Data sources 
In Denmark, every resident is provided a permanent identification number at birth or immigration, 
allowing linkage between nationwide administrative registries at an individual level. In the present 
study, five of these nationwide registries were assessed. The Danish National Patient Registry was 
established in 1978 and includes information on diagnoses and procedural codes. Each outpatient 
appointment and hospital admission is coded at discharge with one primary diagnosis, and if 
appropriate, one or more secondary diagnoses, all according to the 8th revision of the International 
Classification of Diseases, and since 1994 the 10th revision (20). The diagnosis codes used to obtain 
information on comorbidity are considered valid (21). The National Civil Registry contains 
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information on every death occurring in Denmark. The Danish National Prescription Registry 
contains information on every dispensed prescription since 1995, including date of purchase, coded 
according to the Anatomical Therapeutic Classification in Denmark. This registry is considered 
accurate and valid (22). The Danish National Registry on Regular Dialysis and Transplantation was 
established in 1990 and holds information on all Danish patients in renal replacement therapy 
including changes in therapy for end-stage kidney disease and is considered valid (23). The 
nationwide SAB Database was established in 1956 at Statens Serum Institut. This database registers 
more than 94% of staphylococcus aureus positive blood cultures in Denmark, referred from 
Departments of Clinical Microbiology all over Denmark (24).  
 
Population   
The study population comprised all end-stage kidney disease patients initiating renal replacement 
therapy in the period from January 1, 1996 to December 31, 2011 assessed via The Danish National 
Registry on Regular Dialysis and Transplantation. Renal replacement therapy included 
hemodialysis, peritoneal dialysis, and kidney transplantation (transplantation carried out pre-
emptively and after initiation of either hemodialysis or peritoneal dialysis). 
End-stage kidney disease patients initiating or changing renal replacement treatment to either 
peritoneal dialysis or kidney transplantation from hemodialysis were included in the study to allow 
treatment switch and complete analyses of time spent in hemodialysis during follow-up. Hence, 
every change in renal replacement therapy modality was identified and entered time-updated, 
allowing each patient to change renal replacement therapy subgroup (e.g. from hemodialysis to 
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kidney transplantation, adding risk time to more than one subgroup) during follow-up. For 
classification of dialysis modality and hemodialysis vascular access type, detailed information 
including CVC (cuffed and uncuffed), arteriovenous fistula, arteriovenous graft and peritoneal 
catheter were obtained from The Danish National Patient Registry and combined with primary and 
changing treatment modalities of hemodialysis, peritoneal dialysis and kidney transplantation from 
The Danish National Registry on Regular Dialysis. Hemodialysis patients with a failed- or an 
immature arteriovenous fistula added risk time to a cuffed- or an uncuffed central venous catheter 
until the arteriovenous fistula was available for hemodialysis. The data were accessed at individual 
level in collaboration with two independent nephrologists.  
Comorbidities 
Data on comorbidities were retrieved from The Danish National Patient Registry up to five years 
before initiation of renal replacement therapy until event, death or study end. The diagnosis of 
diabetes mellitus was derived from redemption of antidiabetic drugs from The Danish National 
Prescription Registry. 
Outcome 
The outcome of interest was the first event of SAB after initiation of renal replacement therapy in 
the period 1996-2011 and was derived from the nationwide SAB Database. All patients were 
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The present observational registry-based study was approved by the Danish Data Protection Agency 
(ref. 2007-58-0015 / internal ref. GEH-2014-015 I-suite no. 02733). 
Statistical analyses 
Continuous data are presented as mean±standard deviation. Differences between categorical 
variables were analysed with Chi-squared test. Differences between continuous variables were 
analysed with non-parametric tests. The incidence of SAB was based on the number of events in the 
study population divided by the time interval spent in each modality of renal replacement therapy. 
Multivariable Poisson regression was used to determine the association of SAB with each renal 
replacement therapy modality (hemodialysis, CVC (cuffed and uncuffed), arteriovenous fistula, 
arteriovenous graft, peritoneal dialysis and kidney transplantation) and to identify independent risk 
factors for SAB. The model included renal replacement therapy modality time-dependently, 
allowing each patient to change modality during follow-up (e.g. from hemodialysis to kidney 
transplantation, adding risk time to more than one subgroup). Sex, age and comorbidities (diabetes 
mellitus, mitral- and aortic valve disease) were covariates in the models. Comorbidities were 
entered time-dependently at the time each was noted. Diabetes mellitus was noted at the time 
glucose-lowering prescription was purchased. The current calendar year was split and entered into 
the model in bands of five years, and age was included in the model in bands of one year. The 
model was adjusted for the overall time spent in renal replacement therapy, which was split into 
time bands of three periods of 90 days, 270 days, and >270 days until event, death or study end. The 
second period was selected to represent the second quartile distribution of outcome. Poisson trend 
test was performed to test for significant change in the incidence of SAB across the study period. 
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Interaction between the modalities of renal replacement therapy and sex, age, calendar year, 
diabetes mellitus, mitral- and aortic valve disease was tested and found to be non-significant except 
for the overall time spent in each period of renal replacement therapy. Stratified analysis of overall 
time spent in each period of renal replacement therapy was performed to assess this interaction. 
Statistical analyses were performed using SAS version 9.4 (SAS institute, Cary, NC, USA), and 
p<0.05 was considered significant. 
 
Results 
Characteristics of the study population 
A total of 9997 patients initiated renal replacement therapy from January 1, 1996 to December 31, 
2011. At baseline, 6826 patients initiated renal replacement therapy by hemodialysis, 2882 by 
peritoneal dialysis, and 289 were pre-emptive kidney transplanted, Table 1 (Supplemental Tables 1 
and 2). 
Incidence of SAB 
A total of 1278 initial episodes of SAB were identified during the study period in the entire cohort 
of 9997 renal replacement recipients. Hemodialysis accounted for 1119 of the SAB events, 
peritoneal dialysis for 117 and kidney transplanted for 42. SAB reoccurred twice in 40 patients and 
three times in four patients. Recurrence of SAB was defined as at least 90 days apart the previous 
SAB event. The incidence rate of SAB remained constant during the last decade of the study period, 
Figure 1.  
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The overall incidence rate of SAB was 19.3/100 person-years in the first 90 days in renal 
replacement therapy, Figure 2. The incidence rate was significantly higher in hemodialysis 
(27.4/100 person-years) than in peritoneal dialysis (3.3/100 person-years) and kidney transplant 
recipients (7.8/100 person-years). The incidence rate was 36.5/100 person-years in the unknown 
hemodialysis access subset, representing unclassified hemodialysis vascular accesses with 
unavailable information for further categorization.    
The incidence rate of SAB in the first 90 days in hemodialysis patients with uncuffed CVC was 
42.6/100 person-years, in cuffed CVC 24/100 person-years, in arteriovenous fistula 23.6/100 
person-years and in arteriovenous graft 19.3/100 person-years. 
The incidence rate of SAB continued to decrease after 90- and 270 days in every modality of renal 
replacement therapy. 
During the first year in renal replacement therapy, 48.7% of the total number of SAB events 
occurred in the hemodialysis patients, 4.6% in peritoneal dialysis, and 1.1% in kidney transplanted 
patients.  
At the time of SAB, the hemodialysis vascular access was an arteriovenous fistula in 50.8% of 
patients, cuffed CVC in 10%, uncuffed CVC in 7.3%, arteriovenous graft in 0.5% and unclassified 
in 19%.  
Factors associated with SAB      
Figure 3 shows the results of the adjusted multivariable Poisson regression for the first episode of 
SAB in the various modalities of renal replacement therapy. The rate ratio (RR) of SAB was 4.10 
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(95% CI 3.39-4.97) in hemodialysis patients, 0.38 (95% CI 0.27-0.55) in kidney transplanted 
patients, 4.43 (95% CI 2.10-9.53) in arteriovenous graft, 3.40 (95% CI 2.79-4.15) in arteriovenous 
fistula, 5.68 (95% CI 4.39-7.36) in cuffed CVC, and 7.42 (95% CI 5.63-9.79) in uncuffed CVC 
compared with peritoneal dialysis. The risk of SAB did not differ between uncuffed CVC and 
cuffed CVC (RR 1.29 95% CI 0.99-1.69). In the first three months of renal replacement therapy, the 
risk of SAB was 5.96 (95% CI 5.25-6.76) and 1.67 (95% CI 1.42-1.96) for 91-270 days compared 
to >270 days in renal replacement therapy. Diabetes mellitus and male sex were independently 
associated with SAB with RRs of 1.35 (95% CI 1.20-1.51) and 1.15 (95% CI 1.03-1.29), 
respectively. The relation between aortic valve disease (RR 1.07 95% CI 0.82-1.38) or mitral valve 
disease (RR 1.27 95% CI 0.94-1.70) and SAB did not reach statistical significance.  
In the first three months in renal replacement therapy, the risk of SAB was 11.37 (95% CI 7.09-
18.22) in CVC, 7.22 (95% CI 4.49-11.10) in arteriovenous fistula, and 2.07 (95% CI 0.84-5.08) in 
kidney transplanted patients compared to peritoneal dialysis, Figure 4. 
Ninety-day mortality was 5.6%, whereas the mortality rate in the subsequent period (91-270 days) 
was 9.2% in the end-stage kidney disease patients.    
Discussion 
In this nationwide study of end-stage kidney disease patients, the incidence rate of SAB was 4-fold 
higher in hemodialysis patients regardless of vascular access as compared with peritoneal dialysis. 
For hemodialysis patients, vascular access type was important. Patients with a CVC had a higher 
incidence rate of SAB than those with arteriovenous fistula as dialysis access. Of note, risk for SAB 
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did not differ between uncuffed- and cuffed CVC. In addition, the risk was significantly increased 
during the first three months of renal replacement therapy compared to >270 days. The first three 
months in renal replacement therapy constituted a higher risk for SAB in CVC than arteriovenous 
fistula, with both compared to peritoneal dialysis. 
The overall incidence rate of SAB in this end-stage kidney disease study population was 
considerably higher than in the general Danish population (0.026/100 person-years) (24). This 
difference might be explained by impaired immune defense related to uremia and repeated access to 
the vascular system and peritoneum, along with immunosuppressive therapy increasing 
susceptibility to bacteremia in the end-stage kidney disease population (10;25;26).  
In a retrospective case series of 898 patients, Wang et al analysed 366 hemodialysis- and 532 
peritoneal dialysis patients with 191 episodes of bacteremia during 2003-2008 at a single hospital 
(27). Similar to our current data, they found a higher incidence rate of bacteremia in hemodialysis 
than in peritoneal dialysis. However, patients were censored at switch in treatment modality, at 
transplantation and at change in dialysis affiliation.  
Recently, a Danish study by Nielsen et al reported the overall distribution of SAB incidence rates in 
end-stage kidney disease patients, with hemodialysis at the high end and kidney transplanted 
patients at the low end (28). This pattern might be explained by repeated vascular access and the 
local granulocyte defect at the access site in hemodialysis patients (29), which seems to exceed the 
risk of bacteremia related to immunosuppressive therapy in kidney transplanted patients. Moreover, 
Nielsen et al reported a higher overall incidence rate of SAB in patients on peritoneal dialysis than 
kidney transplant patients. We investigated the SAB incidence rate during three time periods of 
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renal replacement therapy and found an initial higher SAB rate in kidney transplanted than in 
peritoneal dialysis patients, which decreased below the rate of peritoneal dialysis after 270 days.    
In a recent large retrospective study of US hemodialysis patients, Nguyen et al analysed the 
incidence rate of overall bacteremia and reported the highest rate in CVCs followed by 
arteriovenous graft and arteriovenous fistula (30). Arteriovenous graft is applied to a limited extent 
in Denmark, which leaves the rate inconclusive. However, the CVCs remain the main contributor to 
high rates of SAB in hemodialysis patients. Taken together, these results emphasize the importance 
of initiating renal replacement therapy with the establishment of an arteriovenous fistula, reducing 
the time of CVC access in an effort to decrease SAB events. 
Previous studies have addressed the risk of infections in CVC with incongruent results. Two 
population studies by Stevenson et al (31) and Tokars et al (32) suggested a possible lower risk of 
infection in cuffed- versus uncuffed CVC. In contrast, Taylor et al (15) found no difference between 
them. Taylor et al included 527 hemodialysis patients and identified 93 first time bacteremia events 
from nine hemodialysis units, enrolled from 1998-1999 with a follow-up of 6 months for each 
patient. Taylor et al censored the patients at switch in treatment modality and at change in dialysis 
unit. The current results are comparable to the findings of Taylor et al, but our cohort of end-stage 
kidney disease patients was national, patients were followed up to a maximum of 16 years, were 
allowed to stay in the study at switch in treatment modality and remained in the study at change in 
dialysis affiliation.     
The mortality rate in hemodialysis patients was remarkably high in the initial period after 
commencement of hemodialysis. Robinson et al (33) reported mortality rates in patients initiating 
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hemodialysis of 26.7/100 patient-years in the first 120 days, decreasing to 16.9/100 patient-years 
and 13.7/100 patient-years at 121-365 days and >365 days, respectively. We found a high mortality 
in end-stage kidney disease patients after initiation of renal replacement therapy within the first nine 
months. In a large cohort including 86,886 patients initiating hemodialysis from 11 countries, Jager 
et al found cardiovascular death as the leading cause of death followed by infections (34). The 
patients were included from the ERA-EDTA registry during 1994-2007, with a mean follow-up of 
1.8 years. We demonstrated a high risk of SAB in CVC and arteriovenous fistula during the initial 
90 days of renal replacement therapy, which declined after 90 days and levelled off after 270 days. 
These results might be explained by the initial high mortality from cardiovascular causes and 
infections, resulting in a continuous selection for less comorbid patients throughout the initial 
period of hemodialysis.   
Diabetes mellitus and male sex constituted an independent risk factor for SAB in accordance with 
previous literature (10;35;36). 
Strengths and limitations 
The study is limited to the observational design. The events in the unknown hemodialysis vascular 
access subset are most likely a combination of cuffed- and uncuffed CVCs, since arteriovenous 
graft and arteriovenous fistula require surgical intervention, misclassification is less likely. In 
addition, the codes denoting the hemodialysis access are not formally validated, thus 
misclassification concerning the differentiation between cuffed- and uncuffed CVC cannot be 
excluded even though the procedural codes in the registry were reviewed manually for each 
individual patient. It should be noted that the cohort of end-stage kidney disease patients is large 
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and nationwide, including every patient initiating renal replacement therapy in the study period. 
Moreover, every change in treatment modality during the study period was tracked at the individual 
level. 
Conclusion       
In a nationwide end-stage kidney disease population, the incidence rate of SAB declined after 90 
days and leveled off after 270 days in hemodialysis, peritoneal dialysis and kidney transplanted. 
The incidence rate of SAB in CVCs was higher than in arteriovenous fistula. SAB risk did not 
differ between cuffed- and uncuffed CVC. Diabetes mellitus, male sex and the first three months in 
renal replacement therapy especially in CVC were independent risk factors for SAB. These results 
emphasize the importance of arteriovenous fistula as the primary vascular access in hemodialysis 
and strongly suggest limited use of CVCs.       
Abbreviations 
SAB: Staphylococcus aureus bacteremia, CVC: central venous catheter, RR: Rate ratio 
Acknowledgements: None.  
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Figure Legends 
Figure 1. Incidence rate of SAB in renal replacement therapy recipients 
 
Figure 2. The incidence rate of SAB in various renal replacement therapy modalities 
*134.6/100 person-years 
HD, hemodialysis; PD, peritoneal dialysis; KT, kidney transplantation; T, total; AV-F, 
arteriovenous fistula; AV-G, arteriovenous graft; C-CVC, cuffed central venous catheter; U-CVC, 
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uncuffed central venous catheter; Un-HD, unknown hemodialysis; 95% CI, 95% confidence 
interval 
 
Figure 3. Risk factors for SAB in patients receiving renal replacement therapy 
*Model adjusted for sex, age, diabetes mellitus, aortic valve disease, mitral valve disease, calendar 
time, renal replacement therapy periods (≤90 days-, 91-270 days- or  >270 days in renal 
replacement therapy). 
†Renal replacement therapy period 1: first 90 days in renal replacement therapy, renal replacement 
therapy period 2: 91-270 days in renal replacement therapy, renal replacement therapy period 3: 
>270 days in renal replacement therapy to event, death, or study end.  
‡ CVC, central venous catheter, RR, Rate ratio, 95% CI, 95% confidence interval 
 
Figure 4. Risk of SAB in renal replacement therapy according to time in renal replacement 
therapy 
*Model adjusted for sex, age, diabetes mellitus, aortic valve disease, mitral valve disease, and 
calendar time 
95% CI, 95% confidence interval 
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